Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

Model scores of the 29,894 trials active now.

Model score 32% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 21% of the time (143 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellstemcarcinomatransplantationdonor
  Phrases that lowered it: participantssafety ofdrugprostateclinical
• Sponsor's past termination rate: 9.3% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 42 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.5% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 76.7% (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis NCT01860170 · started 2012 · scored riskier than 94% of active trials completed
• Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors NCT01323920 · started 2011 · scored riskier than 77% of active trials completed
• Bortezomib in Patients With Chronic Graft Versus Host Disease NCT01672229 · started 2012 · scored riskier than 93% of active trials completed
• A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation NCT00670423 · started 2008 · scored riskier than 83% of active trials completed
• Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant NCT01754389 · started 2013 · scored riskier than 74% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.